2018 May 7. doid: 10.1111/bcp.13550.

Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products (EMEA/CHMP/SWP/28367/07 Rev. 1.

CHDR

van Gerven J, Bonelli M

Commentary on the EMA Guideline on strategies to identify and mitigate risks for first‐in‐human and early clinical trials with investigational medicinal products (EMEA/CHMP/SWP/28367/07 Rev. 1